Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Prepaid Assets (2022 - 2025)

NewAmsterdam Pharma's Prepaid Assets history spans 4 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 92.43% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.8 million, down 92.43%, while the annual FY2025 figure was $1.8 million, 92.43% down from the prior year.
  • Prepaid Assets for Q4 2025 was $1.8 million at NewAmsterdam Pharma, down from $28.1 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $30.7 million in Q2 2025 and bottomed at $1.2 million in Q3 2024.
  • The 4-year median for Prepaid Assets is $5.6 million (2022), against an average of $11.6 million.
  • The largest YoY upside for Prepaid Assets was 2301.54% in 2025 against a maximum downside of 92.43% in 2025.
  • A 4-year view of Prepaid Assets shows it stood at $7.8 million in 2022, then tumbled by 72.87% to $2.1 million in 2023, then soared by 1043.29% to $24.3 million in 2024, then crashed by 92.43% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Prepaid Assets are $1.8 million (Q4 2025), $28.1 million (Q3 2025), and $30.7 million (Q2 2025).